Revitelle (bilastine) is a non-sedating histamine antagonist with a predominant H1-receptor affinity. Bilastine is approved for symptomatic treatment of allergic rhinoconjunctivitis as well as urticaria in young adolescents and adults. The effect and the adverse effects are leveled with the other marketed non-sedating antihistamines. The most frequently occurring adverse effects are: headache, drowsiness, and fatigue. Since the absorption of bilastine is reduced by concomitant intake of food, the tablet should be administered offset of meals. Bilastine is not recommended during concomitant administration of p-glycoprotein inhibitors in patients with moderate to severe renal impairment.
IRF recommends that seasonal and perennial rhinoconjunctivitis as well as urticaria in young adolescents and adults are treated with the cheapest of the following non-sedating histamine antagonists: acrivastine, cetirizine, desloratadine, fexofenadine and levocetirizine.
Revitelle was marketed January 21st 2013. It is currently possible to apply for single reimbursement.